percentage of CD19+ lymphocytes during anti-T cell therapy allowed early modification of the immunosuppressive and antiviral regimen. apparently with favorable alteration in the lymphoproliferative process. This preliminary experience suggests that reduction in overall immunosuppression with concomitant initiation of antiviral therapy for patients with elevated levels of circulating CD19+ B lymphocytes may positively impact the natural history of PJ'LD. Although more extensive evaluation, including larger clinical trials, must validate our findings, peripheral B lymphocyte analysis using mAb and flow cytometry may represent an effective screening strategy . In contrast to kidney and heart. liver transplantation does not seem to benefit from HLA-matching in most patients. Furthermore. lower graft survival rates have been reported when HLA compatibility between donor and recipient is present (]-5l. Since HLA mismatching contributes to liver allograft rejection, we have proposed a dualistic role of HLA in liver transplantation (ll. HLA-matching reduces acute cellular rejection but augments other immunologic mecha· nisms of allograft injury, especially those mediated by major histocompatibility complex (MHCl*-restricted lymphocytes.
In support of this concept, we have recently reported a higher incidence of CMV hepatitis in HLA-DR matched liver transplants. which was also associated with a higher frequency and earlier onset of chronic rejection (6l.
Hepatitis Band C virus (HBV. HCV) infections are a major cause of end-stage liver disease requiring liver transplantation. However. both viruses are difficult to eradicate, ensuring that the viral infection will persist and that recurrent hepatitis will occur in many reCipIents (7. 8) . In the present study we investigated whether HLA matching affects the recurrence of HBV and HCV hepatltls after liver transplantation, From January 1991 to July 1992,98 adult patients underwent orthotopic liver transplantatIOn (OLTxl because endstage liver disease secondary to HBV and/or HCV infections. Of these. 9 (9%) died during the first month after OLTX. The remaining 89 patients constituted the study group. Thirtyone patients (35%) had hepatitis B. 53 (59%) had hepatitis C. and 5 (6%) had Band C hepatitis. All hepatitis B patients Primary immunosuppression included in all patients tacrolimus (FK506) and steroids. Tacrolimus was initially given in a continuous infusion at 0.1 mg/kg!day, which was converted to an oral dose of 0.15 mg/kg!day every 12 hr with the return of bowel function. Subsequent dosage adjustments were guided by the quality of the graft, the presence of rejection, toxicity, and tacrolimus plasma trough level (normal value: <2 ng!ml). Rejection episodes were treated with a 1-g pulse of methylprednisolone or a 5-day taper of high-dose steroids from 200 to 20 mg. Steroid-resistant rejection episodes were treated with a 5-day course of OKT3.
During a follow-up of between 18 and 24 months. 45 of the 89 (51%) liver transplant recipients had recurrence ofhepatitis at (mean:!: sm 259:!: 174 days after transplantation. Recurrence of hepatitis was defined by the presence of portal and parenchymal mononuclear infiltration and isolated hepatocyte necrosis, as evidenced by acidophilic bodies in histopathology. In addition, diagnosis hepatitis B recurrence required the expression of HBsAg and HBcAg by liver cells. detennined by immunoperoxidase techniques. along with positive HBsAg in the serum. The diagnosis of hepatitis C recurrence required the presence of anti-HCV antibodies by a second-generation ELISA (Abbot Laboratories. Abbot Park. ILl. and detection of HCV RNA in the liver biopsy. In 13 of the 31 patients with recurrent hepatitis C, HCV RNA was also investigated in serum specimens. and all them were positive. Other causes of liver dysfunction. such as rejection, drug toxicity, or viral infections by the herpesvirus group ICMV. EBV and herpes simplex). were excluded.
Fourteen of 31 patients (45%) with HBV infection-27 of 53 151'7r) with HCV and 4 of 5 (80%) with HBV and HCV infections-had recurrent hepatitis. The incidence of recurrence of hepatitis was significantly higher for HLA-B-compatible liver transplants recipients. Nineteen of the 45 patients (42'7<:) with recurrent hepatitis shared at least one HLA-B antigen with the donor. In contrast. HLA-B sharing was found in 9 of 44 patients (20O/rl without recurrent hepatitis I P<O.051. One or two HLA-B antigen matching increased the relative risk (Odds ratio) of recurrent hepatitis 2.8 times. There seemed to be no preferential sharing of any particular HLA-B antigen in the recurrent hepatitis group. There were no differences between HLA-B-matched and -unmatched patients In tenns of severity of recurrent hepatitis. No significant associations were found between recurrence of hepatitis and donor-recipient sharing of HLA-A. HLA-DR. and HLA-DQ antigens. Kaplan-Meier analysis showed that HLA-B matching significantly increased the probability of developing recurrent hepatitis from 40'7c to 75,} at two years in patients with HBV infection (patients with HBV and HCV infection are included in this grOUP) (Fig. lAl, and from 39% to 76% in patients with HCV infection (Fig. 1Bl .
These observations suggest that HLA-B sharing between (17, 18) . Infection of a transplanted liver by HBV or HCV leads to the expression of viral antigens, which-in context with MHC class I molecules on the cell surfacecould be recognized by recipient T lymphocytes. HLA matching would permit a more efficient MHC-restricted antigen presentation, thereby augmenting cell-mediated immune responses toward HBV-and HCV-infected liver allografts. Thus, theoretically immunosuppressive therapy should reduce liver injury mediated by immune mechanisms (19) . However, it also increases virus replication, which may be associated with an increased antigen expression and greater spread through the allografted liver. In summary, the findings described in this report provide further support for the concept of a dualistic role of HLA in liver transplantation, and help to explain why survival is poorer with better matches. Although HLA matching reduces acute cellular rejection, it increases the risk of CMV hepatitis and recurrence of HBV and HCV hepatitis. A better understanding of all these different HLA-associated immune mechanisms may lead to improved management strategies in hepatic transplantation.
